Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer
Status:
Unknown status
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
There is a paucity of data on the histopathological response of peritoneal tumor deposits
from colorectal cancer to neoadjuvant chemotherapy. Particularly, no prospective assessment
of chemotherapy-associated histopathological response within the peritoneum has been
performed so far. Therefore, there is an urgent need to conduct a clinical trial aimed at
prospectively assessing the histopathological response within the peritoneum in patients with
peritoneal metastasis from colorectal cancer.
Recently, Loupakis et al. reported that the triplet regimen of 5-fluorouracil, oxaliplatin
and irinotecan (FOLFOXIRI) in combination with bevacizumab significantly improved median
progression-free survival in metastatic colorectal cancer patients from 9.7 to 12.1 months as
compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab. In view of
these data, it is likely that FOLFOXIRI + bevacizumab will also lead to a significant
improvement of the histopathological response within the peritoneum of patients with
peritoneal metastasis from colorectal cancer (pcCRC) as compared with previous standard
chemotherapy.
The investigators hypothesize that FOLFOXIRI + bevacizumab will induce a pCR or major
response in peritoneal tumor deposits in >30% of patients (taking the response rate to
FOLFOX- or FOLFIRI-based neoadjuvant chemotherapy from the published literature as a
reference).